Dyadic International (DYAI) Other Working Capital Changes (2018 - 2026)
Dyadic International (DYAI) posted Other Working Capital Changes of -$620282.0 for Q1 2026, down 23.1% sequentially from -$503898.0 in Q4 2025, and down 267.91% YoY from $369417.6 in Q1 2025.
Dyadic International (DYAI) Other Working Capital Changes (2018 - 2026) Analysis & Trends
Dyadic International has reported Other Working Capital Changes for 9 years, with the latest figure at -$620282.0 in Q1 2026.
- Quarterly Other Working Capital Changes fell 267.91% year-over-year to -$620282.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$452258.0 (down 169.42% YoY) and the FY2025 annual result came in at -$573.0, down 149.02% from the prior year.
- Other Working Capital Changes retreated to -$620282.0 in Q1 2026 per DYAI's latest filing, from -$503898.0 in the prior quarter.
- Over five years, Other Working Capital Changes peaked at $254966.0 in Q3 2025 and troughed at -$217109.0 in Q4 2022.
- A 5-year average of -$21504.4 and a median of -$44908.0 in 2026 frame the typical range for Other Working Capital Changes.
- The widest YoY moves for Other Working Capital Changes: up 2149.7% in 2025, down 38769.04% in 2025.
- Over 5 years, Other Working Capital Changes stood at -$110404.0 in 2022, then surged by 100.39% to $436.0 in 2023, then sank by 5421.33% to -$23201.0 in 2024, then slumped by 2071.88% to -$503898.0 in 2025, then retreated by 23.1% to -$620282.0 in 2026.
- According to Business Quant data, Other Working Capital Changes over the past three periods registered -$620282.0, -$503898.0, and $503314.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn |
| 10 | Dyadic International | 20.18 Mn | 20.18 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -620,282.00 |
| Mar 31, 2026 | -620,282.00 |
| Mar 31, 2026 | -620,282.00 |
| Dec 31, 2025 | -503,898.00 |
| Dec 31, 2025 | -503,898.00 |
| Dec 31, 2025 | -503,898.00 |
| Sep 30, 2025 | 503,314.00 |
| Sep 30, 2025 | 503,314.00 |
| Sep 30, 2025 | 503,314.00 |
| Jun 30, 2025 | 168,608.00 |
| Jun 30, 2025 | 168,608.00 |
| Jun 30, 2025 | 168,608.00 |
| Mar 31, 2025 | -168,597.00 |
| Mar 31, 2025 | -168,597.00 |
| Mar 31, 2025 | -168,597.00 |
| Dec 31, 2024 | -23,201.00 |
| Dec 31, 2024 | -23,201.00 |
| Dec 31, 2024 | -23,201.00 |
| Sep 30, 2024 | 32,160.00 |
| Sep 30, 2024 | 32,160.00 |